Kenvue

Kenvue is an American consumer health company formed from Johnson & Johnson’s former consumer health division. Its portfolio includes brands such as Tylenol, Neutrogena, Listerine, Johnson’s, Aveeno, Band-Aid, Zyrtec, Motrin, Visine, and Rogaine. The business spans self-care medicines, skin health and beauty, oral care, baby care, wound care, and other everyday consumer health categories. Johnson & Johnson announced the separation of its consumer health operations in November 2021, presenting the move as a way to give the consumer business greater strategic focus while allowing Johnson & Johnson to concentrate on pharmaceuticals and medical devices. The business was incorporated in Delaware in February 2022 under the provisional name JNTL, Inc. The Kenvue name was announced in September 2022. It combines “ken,” associated with knowledge, with “vue,” intended to suggest sight or perspective. Kenvue completed an initial public offering on the New York Stock Exchange in May 2023 under the symbol KVUE. The offering priced shares at $22 and raised approximately $3.8 billion, while Johnson & Johnson initially retained a large majority stake. Johnson & Johnson later conducted an exchange offer in July 2023 to complete the separation of the two companies. Kenvue joined the S&P 500 Dividend Aristocrats index in August 2023. The company’s commercial model relies on recognizable, widely distributed consumer brands rather than a single flagship product. Its self-care portfolio includes pain relief, allergy and cold medicines, gastrointestinal products, smoking-cessation products, and eye care. Its beauty and personal-care activities include facial care, acne care, body care, hair regrowth, and skin moisturization. Oral care is led by Listerine, while baby care is associated particularly with Johnson’s. Kenvue also sells wound-care products through Band-Aid and topical medicines through brands including Neosporin and Trosyd. Kenvue has faced investor scrutiny since becoming public. A securities class action filed in 2023 alleged that the company’s registration materials did not adequately describe risks and potential litigation concerning phenylephrine-containing products and questions about the ingredient’s efficacy. The company also experienced leadership and strategic changes in 2025. Thibaut Mongon, its initial chief executive, was terminated in July 2025, after activist investor Starboard Value acquired a stake and its chief executive Jeffrey Smith joined Kenvue’s board. Kirk Perry was subsequently named interim chief executive and, according to the supplied reference material, became permanent chief executive in November 2025. In November 2025, Kimberly-Clark announced an agreement to acquire Kenvue for an enterprise value reported at approximately $48.7 billion. The proposed transaction would combine Kenvue’s consumer health portfolio with Kimberly-Clark brands including Kleenex, Kotex, Huggies, and Softex. Completion was expected in the second half of 2026, subject to customary conditions and approvals. Until completion, Kenvue remains a separately listed public company.

Kenvue originated in Johnson & Johnson’s consumer health division, a business built around household and over-the-counter brands rather than prescription medicines or medical devices. On November 12, 2021, Johnson & Johnson announced that it would separate the division into a new company. The proposed separation included brands such as Aveeno, Band-Aid, Neutrogena, Tylenol, Johnson’s, and Listerine. Johnson & Johnson said the change would allow the consumer operation to pursue its own priorities while the parent company focused on pharmaceuticals and medical devices. The separation occurred during a period when several large healthcare companies were reshaping or divesting consumer operations. It also followed reputational and litigation challenges associated with Johnson & Johnson, including disputes involving opioids and talc products. The consumer business had substantial brand recognition but a different growth and capital profile from Johnson & Johnson’s pharmaceutical and medical-device units. The planned separation therefore served both an organizational and strategic purpose. The new company was incorporated in Delaware in February 2022 under the provisional name JNTL, Inc. It was initially based in the Skillman section of Montgomery Township, New Jersey. In September 2022, Johnson & Johnson announced the Kenvue name. The name was described as combining a term associated with knowledge with a word suggesting vision or perspective. At that stage, the business employed approximately 22,000 people. Kenvue filed for an initial public offering with the U.S. Securities and Exchange Commission in January 2023. The offering took place on May 4, 2023. Approximately 170 million shares were offered at $22 each, raising about $3.8 billion and giving the company an initial equity valuation of roughly $41 billion. Johnson & Johnson retained close to 91 percent of Kenvue after the offering. The listing provided a public valuation for a major consumer health portfolio and occurred amid a subdued U.S. IPO market. In July 2023, Johnson & Johnson launched an exchange offer through which its shareholders could exchange Johnson & Johnson common stock for Kenvue shares. This transaction completed the operational separation and substantially changed the shareholder relationship between the two companies. Kenvue was added to the S&P 500 Dividend Aristocrats index in August 2023. Kenvue’s business is organized around categories including self-care, skin health and beauty, essential health, oral care, and baby care. Its portfolio includes analgesics and fever reducers, allergy and cold remedies, gastrointestinal products, smoking-cessation products, eye care, dermatological treatments, facial care, moisturizers, hair-regrowth products, wound care, and oral hygiene. The company’s broad brand portfolio gives it distribution across pharmacies, supermarkets, mass retailers, e-commerce channels, and healthcare-related outlets in numerous markets. The company’s first chief executive was Thibaut Mongon. Kenvue later faced investor concerns connected with disclosures about phenylephrine products. A securities class action filed in October 2023 alleged that Kenvue’s registration statement did not adequately disclose risks, potential litigation, and efficacy-related issues involving phenylephrine. The allegations were contested matters rather than established findings in the supplied reference material. In 2025, activist investment firm Starboard acquired a stake in Kenvue, and Starboard chief executive Jeffrey Smith joined the company’s board. Kenvue terminated Mongon in July 2025 and began a review of its strategy. Kirk Perry was named interim chief executive and was subsequently identified in the reference material as the permanent CEO from November 2025. On November 3, 2025, Kimberly-Clark announced an agreement to acquire Kenvue. The proposed combination would bring Kenvue’s consumer health brands together with Kimberly-Clark’s household and personal-care brands. The reported enterprise value was approximately $48.7 billion. Kimberly-Clark shareholders were expected to own about 54 percent of the combined company and Kenvue shareholders about 46 percent. Completion was expected in the second half of 2026, meaning the transaction remained pending in the supplied material.

1. 2025Leadership transition and strategy review

   Kenvue changes chief executive leadership after activist investor involvement and begins a strategic review.

   Source
2. 2025Kimberly-Clark acquisition agreement

   Kimberly-Clark announces a proposed acquisition of Kenvue for an enterprise value of approximately $48.7 billion.

   Source
3. 2023Initial public offering

   Kenvue lists on the New York Stock Exchange under KVUE, pricing its IPO at $22 per share and raising approximately $3.8 billion.

   Source
4. 2023Johnson & Johnson exchange offer completes separation

   Johnson & Johnson launches an exchange offer allowing shareholders to exchange parent-company shares for Kenvue shares.

   Source
5. 2023Added to S&P 500 Dividend Aristocrats index

   Kenvue is added to the S&P 500 Dividend Aristocrats index.

   Source
6. 2022JNTL, Inc. is incorporated

   The future Kenvue business is incorporated in Delaware under the provisional name JNTL, Inc.

   Source
7. 2022Kenvue name announced

   Johnson & Johnson introduces Kenvue as the name of the planned standalone consumer health company.

   Source
8. 2021Johnson & Johnson announces consumer health separation

   Johnson & Johnson announces that its consumer health division will become an independent company.

   Source

Science-led, mass-market consumer health and personal-care portfolio built around trusted, globally distributed brands.

• TylenolOver-the-counter pain relief

  A major analgesic and fever-reduction brand marketed in multiple dosage forms and markets. Tylenol is one of Kenvue’s most prominent self-care franchises and is associated primarily with acetaminophen-based products.

• ListerineOral care

  An international mouthwash and oral-care brand offering products designed for rinsing, breath care, plaque control, and broader daily oral-hygiene routines.

• NeutrogenaSkin health and beauty

  A skin-care and beauty brand known for facial cleansers, moisturizers, acne-care products, sunscreens, and other dermatological or cosmetic items. It serves both everyday skin-care and more targeted treatment routines.

• Johnson'sBaby care

  Kenvue’s baby-care portfolio includes cleansers, shampoos, lotions, oils, and related products formulated and marketed for infants and families. The brand also has personal-care extensions in some markets.

• AveenoSkin care

  A skin-care brand centered on moisturization and products for dry or sensitive skin. Its portfolio includes body lotions, facial care, cleansing products, and other everyday dermatological-care offerings.

• Band-AidWound care

  A wound-care brand offering adhesive bandages and related products for minor cuts, abrasions, blisters, and everyday first-aid needs.

• ZyrtecAllergy medicine

  An over-the-counter allergy brand offering products for symptoms associated with allergic rhinitis and related conditions in markets where the brand is sold.

• RogaineHair-regrowth treatment

  A topical hair-regrowth brand positioned around products for hereditary hair loss and related consumer hair-care concerns.

• VisineEye care

  An eye-care brand offering over-the-counter products for common eye symptoms and irritation, subject to the formulations and regulatory permissions of individual markets.

• MotrinOver-the-counter pain relief

  A consumer pain-relief brand associated primarily with ibuprofen products and positioned for relief of common aches, pains, and fever.

• 2025Leadership change and strategic reviewStrategy

  Activist investor Starboard acquired a stake in Kenvue, and Starboard chief executive Jeffrey Smith joined the board.

  What changed. Kenvue terminated Thibaut Mongon as chief executive and initiated a review of company strategy.

  Aftermath. Kirk Perry became interim chief executive and was later identified as the permanent CEO in November 2025.

  Source
• 2025Proposed acquisition by Kimberly-ClarkM&A

  Kimberly-Clark sought to combine its household and personal-care brands with Kenvue’s global consumer health portfolio.

  What changed. Announced a cash-and-stock agreement to acquire Kenvue at an enterprise value of approximately $48.7 billion.

  Aftermath. The transaction was expected to close in the second half of 2026, subject to customary conditions and approvals.

  Proposed enterprise value. Approximately US$48.7 billion (November 2025 announcement)

  Source
• 2023Initial public offeringProduct launch

  Kenvue entered the public market as a large, established consumer-health portfolio during a period of reduced U.S. IPO activity.

  What changed. Priced approximately 170 million shares at $22 each on the New York Stock Exchange under KVUE.

  Aftermath. The offering raised approximately $3.8 billion, while Johnson & Johnson initially retained close to 91 percent ownership.

  IPO proceeds. Approximately US$3.8 billion raised (May 2023)

  Source
• 2023Complete separation through exchange offerM&A

  Following the IPO, Johnson & Johnson still held most Kenvue shares and needed to complete the planned separation.

  What changed. Launched an exchange offer allowing Johnson & Johnson shareholders to exchange parent-company shares for Kenvue shares.

  Aftermath. The transaction completed the intended corporate separation between the two companies.

  Source
• 2021Separate consumer health from Johnson & JohnsonStrategy

  Johnson & Johnson sought to give its consumer health business a distinct strategic and operating focus while concentrating the parent company on pharmaceuticals and medical devices.

  What changed. Announced a plan to establish the consumer health division as a standalone company.

  Aftermath. The new business became Kenvue and later entered public markets, followed by a full share-based separation from Johnson & Johnson.

  Source

• 2023Phenylephrine disclosure securities litigationControversy

  A securities class action filed in the United States District Court for the District of New Jersey alleged that Kenvue’s registration statement contained misleading statements or omissions concerning internal controls, financial reporting, and risks or potential litigation connected with phenylephrine products and questions about their efficacy. The supplied material describes allegations and investor losses, not a final adjudication.

  Source

• 2025Kenvue undergoes leadership and strategy review

  Following activist investor Starboard’s investment and Jeffrey Smith’s appointment to the board, Kenvue terminated CEO Thibaut Mongon and began a strategy review.

  Leadership change
  Source
• 2025Kimberly-Clark announces agreement to acquire Kenvue

  Kimberly-Clark announced a proposed cash-and-stock acquisition of Kenvue at an enterprise value of approximately $48.7 billion, with closing expected in the second half of 2026.

  M&A
  Source
• 2023Kenvue completes initial public offering

  Kenvue began trading publicly on the New York Stock Exchange after pricing its initial offering at $22 per share and raising approximately $3.8 billion.

  Other
  Source
• 2022Consumer health company receives the Kenvue name

  Johnson & Johnson announced Kenvue as the name of the new standalone consumer health company.

  Other
  Source
• 2021Johnson & Johnson announces plan to separate consumer health division

  Johnson & Johnson announced that its consumer health business would become a separate company, separating it from the group’s pharmaceutical and medical-device operations.

  Other
  Source

1. Kenvue
2. Kenvue official website